| NSUN2 | |
|---|---|
| Gene Symbol | NSUN2 |
| Full Name | NOP2/Sun RNA Methyltransferase 2 |
| Chromosomal Location | 5p15.31 |
| NCBI Gene ID | [54888](https://www.ncbi.nlm.nih.gov/gene/54888) |
| OMIM ID | [610202](https://www.omim.org/entry/610202) |
| Ensembl ID | ENSG00000012061 |
| UniProt ID | [Q08J02](https://www.uniprot.org/uniprot/Q08J02) |
| Encoded Protein | [NSUN2 Protein](/proteins/nsun2-protein) |
| Associated Diseases | [Intellectual Disability](/diseases/intellectual-disability), [Dubowitz Syndrome](/diseases/dubowitz-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Autism Spectrum Disorder](/diseases/autism) |
NSUN2 (NOP2/Sun RNA Methyltransferase 2), also known as Misu or SAMMT, is a crucial RNA methyltransferase that catalyzes the 5-methylcytosine (m5C) modification of transfer RNA (tRNA) and other RNA species. This enzyme plays essential roles in RNA processing, translation regulation, and cellular stress responses. NSUN2 has garnered significant attention in recent years due to its critical functions in brain development and its emerging role in neurodegenerative diseases[1].
The NSUN2 gene encodes a 697-amino acid protein belonging to the NSUN family of RNA methyltransferases. It localizes primarily to the nucleus and cytoplasm, where it performs its enzymatic functions. The enzyme uses S-adenosylmethionine (SAM) as a methyl donor to modify specific cytosine residues in target RNAs, a post-transcriptional modification that profoundly impacts RNA stability, structure, and function[2].
| Property | Value |
|---|---|
| Official Symbol | NSUN2 |
| Official Full Name | NOP2/Sun RNA Methyltransferase 2 |
| Also Known As | Misu, SAMMT, NSUN2, TUMOR SUPPRESSOR SUBTYPE |
| Chromosomal Location | 5p15.31 |
| NCBI Gene ID | 54888 |
| Ensembl ID | ENSG00000012061 |
| UniProt ID | Q08J02 |
| Protein Length | 697 amino acids |
| Expression | Ubiquitous; highest in brain, testis, and gastrointestinal tract |
NSUN2 catalyzes the methylation of cytosine residues at position 5 (m5C) in various RNA species, primarily tRNA molecules. This modification occurs at specific positions within tRNA molecules, particularly at positions 34 (the wobble position) and 48 in the anticodon loop[3]. The m5C modification is mediated through a conserved catalytic domain that recognizes specific tRNA structural features.
Key substrate tRNAs for NSUN2 include:
NSUN2-mediated m5C modification affects multiple aspects of RNA biology:
tRNA Stability: The m5C modification enhances tRNA stability by protecting against exonucleolytic degradation. Unmodified tRNAs are more susceptible to decay pathways, leading to reduced translational capacity[4].
Translation Efficiency: Modified tRNAs exhibit improved codon-anticodon pairing efficiency, particularly at the wobble position. This facilitates smooth translation elongation and reduces ribosome stalling, especially during the translation of polyproline sequences and other difficult motifs[5].
Ribosome Biogenesis: NSUN2 localizes to the nucleolus and participates in ribosome biogenesis through modification of ribosomal RNA and processing of pre-rRNA.
Cellular Stress Response: Under various cellular stresses including oxidative stress, UV irradiation, and nutrient deprivation, NSUN2 relocalizes and modifies specific tRNAs to reprogram translation toward stress-response proteins[2:1].
In the brain, NSUN2 plays particularly important roles:
Emerging evidence suggests that NSUN2 dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms[6][7]:
tRNA Hypomethylation: Studies have revealed reduced NSUN2 activity and decreased m5C modifications in AD brain tissue. This hypomethylation leads to:
Protein Aggregation: NSUN2 deficiency promotes the aggregation of amyloid-beta and tau proteins through:
Neuroinflammation: Altered tRNA modifications affect the translation of pro-inflammatory cytokines and chemokines, potentially exacerbating neuroinflammation in AD.
NSUN2 has been implicated in Parkinson's disease through its role in dopaminergic neuron survival[8]:
Mitochondrial Function: NSUN2-mediated modifications are essential for:
Alpha-Synuclein Pathology: NSUN2 deficiency may promote alpha-synuclein aggregation through:
LRRK2 Interaction: NSUN2 has been shown to interact with LRRK2 (Leucine-Rich Repeat Kinase 2), a major PD-causing gene, suggesting potential regulatory interactions in dopaminergic neurons.
Biallelic mutations in NSUN2 cause autosomal recessive intellectual disability with additional features[9][10]:
Clinical Phenotype:
Mechanism: Loss of NSUN2 function leads to:
NSUN2 mutations have been identified as a cause of Dubowitz syndrome, a rare autosomal recessive disorder characterized by[9:1][10:1]:
NSUN2 has been implicated in autism through studies showing:
NSUN2 exhibits region-specific expression in the brain:
Within neurons, NSUN2 localizes to:
NSUN2 expression and activity serve as potential biomarkers:
Strategies for targeting NSUN2 in neurodegeneration:
Several pharmaceutical companies are developing NSUN2-targeted compounds:
NSUN2-related disorders are diagnosed through:
Disease outcomes vary based on:
NSUN2 interacts with several proteins and pathways:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| DNMT3A | Protein binding | Coordinated DNA/RNA methylation |
| YBX1 | Protein binding | m5C reader function |
| ELAVL1 | Protein binding | mRNA stabilization |
| RPL22 | Protein binding | Ribosomal function |
| XRN2 | Enzymatic | tRNA processing |
| DICER1 | Protein binding | miRNA processing |
Leong WZ, Tan SH, Ng PP, et al. The RNA methyltransferase NSUN2 in brain development and disease. Frontiers in Molecular Neuroscience. 2019. ↩︎ ↩︎
Martinez FJ, Pantoja C, Gonzalez-Aguado R, et al. NSUN2-mediated m5C modification of tRNA in cellular stress response. Nature Communications. 2020. ↩︎ ↩︎
Bhatt K, Singh H, Sharma P, et al. Role of RNA methylation in neurodegenerative diseases. Journal of Molecular Neuroscience. 2019. ↩︎
Tu J, Ng SH, Yeung Y, et al. NSUN2 deficiency leads to impaired translation and neurodevelopmental defects. Cell Death & Disease. 2022. ↩︎
Shinoda S, Suzuki M, Yamanaka Y, et al. NSUN2-mediated m5C modification of tRNAArg regulates neuronal survival. Journal of Neurochemistry. 2022. ↩︎
Fischer J, Wang L, Bordered E, et al. tRNA modifications and translational control in Alzheimer's disease. Acta Neuropathologica Communications. 2021. ↩︎
Yang L, Cao L, Lin Y, et al. Epitranscriptomic alterations in Alzheimer's disease brain tissue. Brain. 2023. ↩︎
Liu J, Wang H, Sun J, et al. Emerging role of RNA modifications in Parkinson's disease. Frontiers in Aging Neuroscience. 2023. ↩︎
Khan MA, Rafiq MA, Noor A, et al. NSUN2 mutations cause autosomal recessive intellectual disability. American Journal of Human Genetics. 2012. ↩︎ ↩︎
Hori Y, Takeda M, Kawaguchi M, et al. NSUN2 mutations in patients with Dubowitz syndrome - phenotype expansion. American Journal of Medical Genetics Part A. 2022. ↩︎ ↩︎